Browse the evidence

Tirzepatide (5-15 mg weekly) achieves mean weight loss of 15-21% in adults with BMI ≥27 kg/m², demonstrating superior efficacy compared to placebo and potentially other GLP-1 agonists.

Tirzepatide is a weekly injection available in doses up to 15mg. It can help you lose over 20% of your body weight if you have a BMI over 27. Side effects like nausea are common but often manageable. It is approved for obesity management in the US and UK.

Obesity medications are indicated for adults with BMI ≥30 kg/m² (or ≥27 kg/m² with complications) and must be used in conjunction with lifestyle interventions to optimize effectiveness and health outcomes.

If you have obesity or are overweight with a related health issue, medications are a valid medical option, but they work best when paired with diet and exercise changes. You must meet specific BMI criteria (usually 30+, or 27+ with health issues). Crucially, if you start a medication and don't lose at least 5% of your body weight after 12 weeks at the maximum dose, you should stop it, as it likely won't work for you. However, for those who respond, these drugs can significantly improve health markers and quality of life.

GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual agonists (Tirzepatide) provide superior weight loss and metabolic benefits compared to older agents like Orlistat or Phentermine, with Semaglutide and Tirzepatide showing the highest efficacy.

Newer injectable medications like Semaglutide and Tirzepatide are significantly more effective for weight loss than older oral drugs like Orlistat. Tirzepatide, in particular, has shown high efficacy in trials, with many users losing 15-20% of their body weight. These are weekly injections and are generally well-tolerated, though gastrointestinal side effects are common during dose escalation.

Bariatric surgery and pharmacotherapy (e.g., GLP-1 agonists) are indicated for many patients with obesity to achieve and maintain weight loss, especially when lifestyle interventions fail.

If lifestyle changes aren't enough, talk to your doctor about medication or surgery. These treatments target the biology of obesity and can significantly improve health conditions like diabetes and heart disease.

Chronic pharmacotherapy with GLP-1 receptor agonists (semaglutide 2.4 mg) and dual agonists (tirzepatide 10-15 mg) produces significantly greater and more sustained weight loss than behavioral interventions alone by neutralizing counter-regulatory physiological mechanisms.

If you have obesity, lifestyle changes alone often fail long-term because your body fights back by increasing hunger hormones. New medications like semaglutide (weekly injection) or tirzepatide (weekly injection) work by overriding this biological defense, allowing for significantly greater weight loss (often >15%) than diet and exercise alone. These are intended for chronic use to maintain results.

Tirzepatide (10-15 mg) produces greater mean weight loss than semaglutide (2.4 mg) in head-to-head comparisons, achieving reductions of up to 20.9%.

Tirzepatide is a weekly injection that targets two hormones (GIP and GLP-1) to maximize weight loss, often resulting in ~20% body weight reduction. It requires slow dose escalation to manage stomach side effects.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) are effective pharmacotherapies for obesity, producing significant weight loss and cardiovascular benefits.

GLP-1 medications like semaglutide are highly effective for weight loss and cardiovascular health. They are a standard treatment for obesity, not a cosmetic fix. Discuss them with your doctor.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) and multi-agonists (retatrutide, CagriSema, survodutide) produce clinically significant weight loss (typically >10-20%) in adults with obesity, with efficacy increasing with dose and number of receptor targets.

GLP-1 based medications (like semaglutide and tirzepatide) are highly effective for significant weight loss (15-20%+) in adults with obesity, often outperforming lifestyle changes alone. They work by targeting hormonal receptors to reduce appetite and slow digestion. While effective, they require medical supervision due to potential side effects like nausea, which usually subside with dose titration. They are indicated for those with a BMI over 27 with complications or over 30.

Unimolecular polypharmacology using dual (GLP-1R/GIPR or GLP-1R/GCGR) or triple (GLP-1R/GIPR/GCGR) agonists produces superior weight loss and glycemic control compared to single-agonist GLP-1 receptor agonists.

If you have obesity or type 2 diabetes, newer medications that target multiple hormones (GLP-1, GIP, and Glucagon receptors) like tirzepatide or retatrutide are significantly more effective for weight loss and blood sugar control than older single-target drugs like semaglutide. These are taken as once-weekly injections. While they can cause stomach issues, they are generally well-tolerated and offer superior results. Consult a doctor to see if you qualify for these treatments.

Triple agonists (GLP-1R/GIPR/GCGR) such as retatrutide achieve greater weight loss than dual agonists by combining satiety signals with increased energy expenditure.

For severe obesity, the newest class of drugs (triple agonists like retatrutide) targets three hormones to maximize weight loss, achieving up to 24% body weight reduction in clinical trials. This is higher than dual-agonist drugs. These are weekly injections. They are currently in clinical development/trials for broader approval. Discuss with your doctor if you are a candidate for these advanced therapies.

Semaglutide promotes significant weight loss in individuals with obesity, both with and without type 2 diabetes.

If you have obesity, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to produce significant weight loss, often exceeding 15% of body weight, when combined with lifestyle changes.

Tirzepatide treatment significantly improves health-related quality of life (HRQoL) across physical, mental, and psychosocial domains in adults with obesity or overweight, with improvements generally scaling with the magnitude of weight loss.

If you have obesity or overweight and have struggled to lose weight through lifestyle changes alone, adding tirzepatide (after achieving initial loss via diet/exercise) can significantly boost your quality of life. This isn't just about weight; it's about better physical function, less pain, and improved mental health. The more weight you lose, the more your quality of life improves, especially if you had physical limitations before starting.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes compared to placebo and other active comparators.

If you have type 2 diabetes, tirzepatide is a once-weekly injection that can significantly lower your blood sugar and help you lose weight. It works by mimicking hormones that regulate blood sugar and appetite. While it can cause stomach issues like nausea, these often improve over time. It is more effective than some other common diabetes medications in lowering blood sugar and reducing weight.

Unimolecular GIPR:GLP-1R coagonists (e.g., tirzepatide) achieve superior body weight loss compared to GLP-1R monoagonists (e.g., semaglutide) in both diabetic and non-diabetic obese populations, with efficacy scaling with dose without compromising tolerability.

If you are treating obesity with medication, combining GIP and GLP-1 receptor activation (like tirzepatide) yields significantly more weight loss than activating only the GLP-1 receptor (like semaglutide). This combination does not increase the side effects that typically limit treatment, allowing for higher effective doses.

Semaglutide 2.4 mg once weekly significantly reduces major adverse cardiovascular events (MACE) and all-cause mortality in individuals with obesity and established atherosclerotic cardiovascular disease (ASCVD), regardless of diabetes status.

If you have obesity and established heart disease, semaglutide 2.4 mg once weekly is a preferred first-line treatment to significantly reduce your risk of heart attacks, strokes, and death, even if you do not have diabetes. This should be combined with lifestyle therapy.

Semaglutide 2.4 mg once weekly is the preferred first-line anti-obesity medication for individuals with obesity and chronic kidney disease (CKD), including non-diabetic populations, due to significant reductions in renal endpoint progression.

If you have obesity and chronic kidney disease, semaglutide 2.4 mg once weekly is the preferred first-line treatment to significantly slow kidney function decline and reduce the risk of needing dialysis or kidney replacement therapy, even if you do not have diabetes.

Tirzepatide 15 mg once weekly is preferred for individuals with obesity and prediabetes when greater weight loss is needed, achieving a 94% risk reduction in diabetes progression over 72 weeks.

If you have obesity and prediabetes, tirzepatide 15 mg once weekly is a preferred treatment to significantly reduce your risk of developing type 2 diabetes and achieve substantial weight loss, especially if lifestyle changes alone are not enough.

Chronic exercise training leads to structural and metabolic adaptations, including mitochondrial biogenesis (via PGC-1a) and muscle hypertrophy (via mTORC), which improve energy efficiency and force generation.

Consistent training changes your body's machinery. Your muscles become better at producing energy (mitochondria) and stronger (hypertrophy). This makes daily activities easier and improves your overall metabolic health over time.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) and triple agonists (e.g., retatrutide) produce significantly greater reductions in body weight and HbA1c compared to selective GLP-1 receptor agonists or placebo in individuals with type 2 diabetes and obesity.

For individuals with obesity or type 2 diabetes, dual GIP/GLP-1 agonists like tirzepatide offer superior weight loss and blood sugar control compared to older GLP-1-only drugs. Treatment typically starts at a low dose (2.5 mg weekly) and increases gradually to 5, 10, or 15 mg to manage side effects. Clinical trials show up to 20% body weight reduction in non-diabetic obese adults over two years.

GLP-1 receptor agonists (semaglutide, liraglutide) and dual GLP-1/GIP agonists (tirzepatide) produce clinically significant weight loss (10-21%) and reduce obesity-related cardiovascular and metabolic complications.

If you have obesity, newer GLP-1 or GLP-1/GIP medications (like semaglutide or tirzepatide) are highly effective, often producing 15-20% weight loss when combined with lifestyle changes. These drugs also significantly improve cardiovascular risk factors. Discuss these options with your doctor, especially if you have a BMI over 30 (or 27 with health issues).

Tirzepatide, a dual GLP-1/GIP receptor agonist, produces greater weight loss (up to 21%) and superior body composition changes compared to other anti-obesity medications.

Tirzepatide is currently one of the most effective weight-loss drugs available, capable of producing ~20% weight loss. It also improves blood pressure, blood sugar, and lipid profiles. It requires weekly injections and lifestyle changes.

Tirzepatide (15mg weekly) achieves 20.9% weight loss, with 50-57% of users losing >= 20% body weight, rivaling bariatric surgery.

Tirzepatide 15mg weekly can lead to ~21% weight loss. Over half of users lose 20% or more. This is a powerful option for those with comorbidities.

Once-weekly subcutaneous semaglutide 2.4 mg produces significantly greater weight loss in adults without type 2 diabetes (mean -11.57%) compared to those with type 2 diabetes (mean -6.34%).

If you have Type 2 Diabetes, expect semaglutide 2.4 mg to work, but anticipate roughly half the weight loss percentage compared to someone without diabetes. This is due to metabolic factors like insulin resistance and 'glycemic buffering' (where improved blood sugar control reduces calorie loss through urine). Manage expectations by focusing on metabolic health benefits alongside weight metrics, as the drug remains clinically effective for both groups.

GLP-1-based peptide therapeutics achieve 15–25% body weight loss with once-weekly dosing, surpassing the efficacy of previous small-molecule drugs and matching bariatric surgery outcomes.

GLP-1 therapies like semaglutide and tirzepatide offer a powerful medical option for obesity, achieving 15-25% weight loss with once-weekly injections. This efficacy rivals bariatric surgery but without the surgical risks. However, these drugs require ongoing use to maintain results, and access can be limited by cost and supply. Consult a healthcare provider to determine if this treatment is appropriate for your specific health profile.